Rapamycin for Longevity and the Controversy over Pediatric Vaccinations

In this episode of After Hours Clinic, Andrew Lane and Dr. David Janarious examine two controversial and rapidly evolving topics in modern medicine: rapamycin and vaccine skepticism. Dr. Janarious breaks down the science behind rapamycin, a low-cost transplant medication now being studied for its potential role in longevity, muscle preservation, and ovarian aging. They analyze recent clinical trials, discuss the limitations of current data, and explore why the drug continues to generate interest in the biohacking and anti-aging communities. The conversation then shifts to vaccines, informed consent, and the growing tension between physicians and patients. Together, they unpack changing attitudes toward medical authority, individualized care, and the importance of transparent risk-benefit discussions in today’s healthcare landscape.  Key Points From This Episode: [00:00:00] Introduction to rapamycin and its growing role in longevity discussions. [00:01:41] How rapamycin works through mTOR inhibition and cellular “housekeeping.” [00:03:14] Mouse studies showing lifespan extension with rapamycin treatment. [00:05:47] Why human longevity trials are difficult and researchers focus on aging markers instead. [00:06:46] Overview of the 12-week rapamycin exercise study in sedentary older adults. [00:08:15] Discussion of disappointing trial results and limitations of the study design. [00:10:26] Explanation of epigenetic clocks and biological aging measurements. [00:12:04] Why current biological age testing may still be premature. [00:13:27] Safety considerations and adverse events associated with rapamycin use. [00:14:16] Why the recent rapamycin study does not end interest in the drug’s longevity potential. [00:16:15] Breakdown of the PEARL trial and changes in lean muscle mass. [00:17:15] Significant muscle gain findings in women taking higher-dose rapamycin. [00:19:19] Improvements in arthritis-related pain scores reported in the PEARL trial. [00:20:36] Connections between rapamycin benefits in female mice and human trial findings. [00:21:51] The VIBRANT trial and preliminary findings on ovarian aging reduction. [00:23:47] Ongoing rapamycin studies and thoughts on prescribing it off-label. [00:24:43] Comparison of rapamycin with other longevity-focused medications like GLP-1s and SGLT2 inhibitors. [00:26:23] Transition into discussion around vaccine hesitancy and physician burnout. [00:27:20] Pediatricians expressing frustration over increasing vaccine skepticism among parents. [00:28:47] Criticism of paternalism within the medical establishment. [00:30:50] The importance of informed consent and discussing vaccine risks transparently. [00:32:28] Concerns about dismissing patient questions instead of addressing them directly. [00:33:22] Debate over pediatric practices dismissing unvaccinated families. [00:35:12] Discussion about shared medical decision-making and patient autonomy. [00:36:31] How Better Life’s care philosophy emphasizes collaboration with patients. [00:37:52] Why many physicians may not fully understand the vaccine data themselves. [00:39:44] Dr. Janarious shares a personal example of re-evaluating assumptions about alkaline diets. [00:41:38] Potential positive outcomes from greater public involvement in medical decisions. [00:42:33] The need for more individualized and prioritized vaccine recommendations. [00:43:01] Vaccines Dr. Janarious strongly supports, including measles, meningococcal, and HPV vaccines. [00:47:09] Why modern healthcare conversations require more collaboration and nuance. [00:49:03] Final thoughts on avoiding conflict and improving doctor-patient communication.   Links:  Better Life: https://www.joinbetterlife.com/   Dr. David Janarious on LinkedIn: https://www.linkedin.com/in/david-janarious-8b6073280   Production and editing by The Podcast Consultant: https://thepodcastconsultant.com